Trials yielding both positive and negative results for supplemental chromium in hyperlipidaemia have been reported.
Currently, it is unclear what circumstances or conditions and type of subjects are most likely to respond to treatment, so in practice a treatment trial period is often used to establish usefulness in individual patients.
A placebo-controlled trial using chromium tripicolinate (equivalent to 200/jq chromium/day) for 42 days found a reduction in total cholesterol, LDL and apolipoprotein B (the major protein of the LDL fraction) with a slight increase in HDL and a significant increase in apolipoprotein A1 (the major protein of the HDL fraction) (Press et al 1990). Another RCT of 40 hypercholesterolaemic subjects found that chromium polynicotinate (equivalent to 200 fjg elemental chromium) twice daily for 2 months decreased total (10%) cholesterol and LDL-cholesterol (14%) (Preuss et al 2000).
A prospective, double-blind, placebo-controlled crossover study was performed with 30 subjects with type 2 diabetes. Triglyceride levels were significantly reduced (17.4%) and HDL levels increased during the 2 months' chromium picolinate supplementation (Lee & Reasner 1994). This is further supported by other trials (Bahijri 2000).
Another double-blind, placebo-controlled randomised study of young, non-obese adults taking chromium nicotinate (equivalent to 220^g elemental chromium) for 90 days found no statistically significant differences in lipid levels (total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides) at this dose (Wilson & Gondy 1995). Similar results were found in older, non-obese subjects taking 1000 fjg chromium picolinate for 8 weeks (Amato et al 2000) suggesting that subjects without identified pre-existing hypercholesterolemia or other conditions predisposing them to hypercholesterolemia may not respond to treatment. However, a prospective, double-blind, placebo-controlled crossover study of mostly hispanic patients with type 2 diabetes also elicited disappointing results, finding that only triglyceride levels were significantly reduced (17.4%) (Lee & Reasner 1994).
Was this article helpful?
Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...